The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
HH,
I accept you have tried to factor in additional risk factor for general oncology within your estimate should we consider the lower end of your proposed range .
The reality is neither you or I know what’s an appropriate percentage success rate for this particular trial.
I’ve highlighted a very similar Cat-T AML trial that did not succeed and subsequently withdrew. I did so for balance to the frequent proposition here that Hemo’ Car-T will progress through Ph1 trial is almost a given fact, to which I consider your posts suggesting the same.
Whilst it may well succeed, it’s important not to underestimate the particular difficulties specific to AML and on that point i’m sure you’d agree.
A positive ,.. Prevail .
AIMO
HH,
You’re making the same mistake you did when estimating the percentage chance of success in IND clearing.
That mistake being to ignore the particular difficulties with AML and off target complications.
Your 50-75% phase1 success rate is an average which does not make specific considerations and is therefore inappropriate.
Have a look at this.
Cart-T for AML phase 1 , …whats the status ?
AIMO
https://clinicaltrials.gov/study/NCT03904069?intr=FLT3%20CAR-T%20AMG%20553&rank=1
JFH,
Two things.
1. Thank you for final agreement within last paragraph.
2. You appear to have specific information that’s not in the public domain and not simply surmised . Interesting!
Cyrox was spot on. Stop the ramping there’s no need and it actually reflects badly on the Company. That’s also applicable to those holding the RNS pen.
AIMO
JFH,
You’re correct , Prevail did not invest as an observer.
Lot’s of words but you didn’t answer the question !
What do Prevail get in return for the premium paid ?
I suggested the answers within the warranties.
It could be future stock and dilution for shareholders.
I suppose knowing you can’t continue to ignore the Elephant in the room , you’ll spin a story on they’re simply excited about the opportunity and not too concerned in securing financial guarantees for the premium paid.
AIMO
Cyrox,
Wow…honesty on this board, well done!
Hopefully you also found the explicit need to describe the percentage premium paid within the RNS as very disagreeable as did i…why was that required?
I wonder if it contributed to some of the more mathematically challenged jumping to their 6p SP conclusions.
You ask why the premium?
The answers will be within the warranties.
It would be reasonable to conclude Prevail will have negotiated future financial offsets to the premium paid. Could that be through future milestone stock offer and dilution?
AIMO
HH,
You’re not stupid!😉
JFH,(95%)
I’m sorry but there are some negative aspects to the recent RNS’s which you’ve either overlooked in ignorance or deliberately. There’s also a big positive you’ve missed.
Anyway, apparently I’m a dirty, threatening, trader who’s opinions are insignificant so i’ll leave you to it.
Just a final thought, why is the SP not at 6p ?
This board was told by multiple posters that had to be the base level if you interpret the RNS how you have.
Good luck.
AIMO
HT,
I don’t like to , particularly when others are struggling in their positions. It’s called empathy and modesty, try it one day.
Offer remains open to answer HH’s conundrum…just ask!
Ps
Out until pm so no quick response, sorry.
HH,
Should you or others want a realistic answer to the questions you’ve posed , just ask.
I suspect you won’t as any alternative opinion to that of the most absurdly optimistic, is not tolerated on this board !
AIMO
JFH,
You've misunderstood the question!
All I'm asking is would he need to notify market within 5 days ?... not has he or is he.
You might want to look back to last weeks SP though !
Appreciate any informed answer to my original question
My understanding is the CEO (VS) is required to notify the company and they subsequently the market, within 5 days of exercising the options .
I’m not 100% sure on this and would appreciate others more knowledgeable advice if correct or otherwise?
The answer would determine a new position for me.
Thanks in advance.
Micky,
My opinion and as simplistic as requested;
It’s effectively a loan , required to fund works .
The worth or otherwise to shareholders will depend on the details within the warranties, which are not given.
The short term worth will likely be a rise today but to say 6p will now be the base, i think reflects lack of understanding in the RNS.
For those who really want to dissect, “Expect , Initial, Warranties” the words to consider at length.
I think and hope it’s goodbye time.
AIMO
HH,
Sorry, my post is absolutely factual, all based on the content of the company issued RNS and FDA IND process documents.
Please advise with reference to the documents highlighted any inconsistencies within my post ?
I think you’ve offered enough incorrect opinion within your recent posts for any reasonably educated to realise the same. Even JFH had to correct you and that demonstrates just how wrong you are with your opinions.
AIMO
Mr I,
HH has claimed (incorrectly) that the Complete Response has been issued and as such CH will be lifted or CR rejected, latest mid October( 30 day FDA window).
Why is this so hard !!
Hemo’ now have a plan to execute involving further testing prior to submission of their complete response to the FDA.
Should they execute that plan all as their proposal , then within 30 days of submittal date , CH will be lifted and H Car-T cleared.
No timeline has been offered for anticipated completion of the necessary works, only that they will be carried out expeditiously.
Factually, CR could be submitted anytime following the completion of the works described within the RNS and 1year from CH.
That’s it…get it or do i need to get the crayons out !?
AIMO
HH,
Please stop !
If it was a complete response then the company simply awaits the FDA decision within a 30day period .
That’s not the case!
They are working on the fix as stated within the RNS.
It was not their CR !
Hopefully you’ll take a breath, consider the facts and understand. I know you’re intelligent and will get it sooner or later.
AIMO
Mr I,
I’m not in a battle and sorry you feel that’s what it is.
I will though correct those who misinterpret the facts, either deliberately knowing or through ignorance.
True, i was expecting some news for a push to Tranche 1 SP , and that hasn’t happened…yet !
AIMO
HH,
Please stop with the fiction !
The company have NOT submitted a complete response as you claim.
The company have advised within the RNS that the FDA are satisfied with their “Plan” to resolve.
The plan now has to be executed inclusive further testing.*
Upon completion the company will THEN submit their complete response and FDA then review for adherence to the plan prior to clearing with lift of CH.
No more stories today please, don’t have time to correct!
* Preliminary testing as mentioned within RNS , determines final testing for approval to follow.
AIMO